# PK Study of Anti-TB Drugs

> **NCT02457208** · PHASE1 · COMPLETED · sponsor: **University of Oxford** · enrollment: 61 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Isoniazid (H)
- **DRUG:** Rifampicin (R)
- **DRUG:** Pyrazinamide (Z)
- **DRUG:** Ethambutol (E)

## Key facts

- **NCT ID:** NCT02457208
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-07
- **Primary completion:** 2018-01-14
- **Final completion:** 2018-01-14
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2018-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02457208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02457208, "PK Study of Anti-TB Drugs". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02457208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*